<DOC>
	<DOCNO>NCT02824575</DOCNO>
	<brief_summary>The purpose study determine safety tolerability rebastinib combine antitubulin therapy paclitaxel eribulin patient advance breast cancer .</brief_summary>
	<brief_title>Rebastinib Plus Antitubulin Therapy With Paclitaxel Eribulin Metastatic Breast Cancer</brief_title>
	<detailed_description>Metastasis primary cause death breast cancer , invasive carcinoma cell mouse rat mammary tumor co-migrate accompanied macrophage towards intravasation site . The intravasation occur sit TIE2-expressing macrophage , mena-expressing tumor cell , endothelial cell direct contact , form micro-anatomic structure call tumor micro-environment metastasis ( TMEM ) . Ablation presence activity TMEM associate macrophage block intravasation TMEM demonstrate essential role perivascular macrophage TMEM function . Rebastinib , TIE2 inhibitor , block TMEM assembly function in-vivo in-vitro assay . We hypothesize rebastinib combine antitubulin therapy ( eribulin paclitaxel ) could improve clinical outcome breast cancer prevent intravasation TMEM sit prevent metastasis .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Histologically confirm adenocarcinoma breast HER2 ( human epidermal growth factor receptor 2 ) negative ; base ASCO ( american society clinical oncology ) / CAP ( college American Pathologists ) guideline : ( ) IHC ( immunohistochemistry ) 1+ negative IHC 0 negative ; ( b ) ISH ( situ hybridization ) negative use single probe ISH ( average HER2 copy number &lt; 4.0 signals/cell ) , dual probe ISH ( HER2/CEP17 ratio &lt; 2.0 , average HER2 copy number &lt; 4.0 signals/cell ) 2 . Metastatic breast cancer amenable potentially curative surgery . Patients must disease measurable and/or nonmeasurable defined RECIST 1.1 criterion 3 . Prior chemotherapy and/or endocrine therapy . Patients assign arm A arm B depend prior exposure paclitaxel eribulin . Arm A : Rebastinib plus paclitaxel : Up two prior nontaxane chemotherapy regimens metastatic incurable locally advanced disease permit ( prior paclitaxel , docetaxel , eribulin metastatic disease ) ..Prior therapy paclitaxel docetaxel neo/adjuvant set allowable least 6 month interval last adjuvant/neoadjuvant paclitaxel docetaxel dose recurrence . Arm B : Rebastinib plus Eribulin : Patients must previously receive least two chemotherapeutic regimen treatment metastatic disease ( prior eribulin , prior paclitaxel , nabpaclitaxel , docetaxel allow ) . Prior therapy include taxane either adjuvant metastatic setting . Arms A B : Patients hormone receptor positive disease must progressive disease least 2 line endocrine therapy , include one endocrine regimen use combination approve CDK 4/6 ( cyclindependent kinase ) inhibitor ( eg , palbociclib ) . Relapse receive within 6 month complete adjuvant endocrine therapy may consider failure one prior endocrine regimen 4 . Female age &gt; 18 year . Because breast carcinoma disease adult rarely occur child , child exclude study . In addition , safety rebastinib pediatric patient evaluate . 5 . ECOG ( Eastern Cooperative Oncology Group ) performance status 0 1 . 6 . Normal organ marrow function define within 2 week registration ( except specify otherwise ) : Leukocytes &gt; 3,000/µL ; Absolute neutrophil count &gt; 1,500/µL ; Platelets &gt; 100,000/ µL Hemoglobin &gt; 9 g/dL ; Total bilirubin ( within normal institutional limit ) AST ( aspartate aminotransferase ) /ALT ( alanine aminotransferase ) &lt; 2.5 X institutional upper limit normal ; Creatinine ( within normal institutional limit ) ; EKG QTc &lt; 450 msec ( female ) Left ventricular ejection fraction institutional low limit normal ( echocardiogram within 12 week registration ) ; Glucose ( within normal limit ) Serum calcium &amp; phosphorus ( within normal institutional limit ) ; Negative urine serum BHCG ( BetaHuman Chorionic Gonadotropin ) 7 . No significant ocular disease : No prior know history retinal neovascularization , macular edema macular degeneration . Patients without history require baseline ophthalmologic exam part screening , must evidence retinal neovascularization , macular edema macular degeneration screen exam order eligible . 8 . No active cancer : Patients must diseasefree prior invasive malignancy &gt; 2 year exception curativelytreated basal cell squamous cell carcinoma skin , carcinoma situ cervix . Patient follow prior concurrent diagnosis eligible : lobular carcinoma situ , contralateral ductal carcinoma situ , contralateral invasive ductal and/or lobular carcinoma . 9 . Women childbearing potential must pregnant breast feeding . They must also agree use adequate contraception ( hormonal barrier method birth control ) breast feed prior study entry , duration study participation , 30 day completion protocol therapy . Should woman become pregnant suspect pregnant participate study 30 day completion protocol therapy , inform treat physician immediately . 10 . Ability understand willingness sign write informed consent document . 11 . At least 30 day major surgery study enrollment , full recovery . 12 . Concomitant therapy bisphosphonates , RANKL inhibitor growthcolonystimulating factor ( GCSF ) allow per physician decision . 13 . Expansion cohort : Patients expansion cohort must CTC ( TelomeScan ) drawn screen phase eligibility criterion meet , must CTCpositive order eligible enrollment expansion cohort . 1 . History allergic reaction attribute compound similar chemical biologic composition Rebastinib agent use study ( e.g. , Cremophor ) 2 . History cardiac disease , include : ( ) myocardial infarction within 6 month start study , ( b ) history QTc ( correct QT interval ) prolongation QTc &gt; /= 450 msec screen EKG , history additional risk factor Torsade de pointes ( e.g. , heart failure , hyperkalemia , family history long QT syndrome . ( c ) Use concomitant drug prolong QT/QTc interval . ( see `` Study reference manual '' detail ) ( ) New York Heart Association class III IV heart disease , ( e ) , active ischemia uncontrolled cardiac condition angina pectoris , clinically significant cardiac arrhythmia require therapy . 3. bIntercurrent illness would substantially increase risk treatment associate complication ( e.g. , active infection , uncontrolled diabetes mellitus hypertension ) and/or psychiatric illness/social situation would interfere patient 's ability comply treatment regimen . 4 . Patients HIV infection exclude study possible pharmacokinetic interaction Rebastinib antiretroviral therapy . 5 . Patients untreated brain metastasis exclude . Patients prior history brain metastasis eligible receive prior brain radiation , improve stable intracranial disease least 3 month completion last course radiation , take corticosteroid treatment brain metastasis . Patients prior history brain metastasis meet eligibility criterion 6 . Treatment chemotherapy regimen within past 2 week . 7 . Treatment trastuzumab , bevacizumab target therapy within past 4 week . 8 . Patients recover ( i.e. , CTCAE Grade ≤1 baseline ) adverse event due previously administer agent , exclude alopecia . 9 . Patients Grade &gt; 1 neuropathy 10 . Patients uncontrolled hypertension ( define systolic blood pressure &gt; 150 and/or diastolic blood pressure &gt; 90 mm/mg ) . 11 . Patients malabsorption syndrome illness could affect oral absorption</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>metastasis</keyword>
	<keyword>tumor micro-environment</keyword>
</DOC>